CastleVax is the proven technology that will bring safe vaccines for all humans, everywhere. Our state-of-the-art platform for producing first-in-class vaccines uses Newcastle Disease Virus (NDV) to enable rapid development of safe and highly immunogenic viral vectors that are easy to deliver and store, and can be administered via injection or intranasally.
| Website | https://www.castlevax.com |
| Employees | 7 (4 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Vaccine Technology, Vaccine Development, Vaccine Production, Vaccine Platform, Viral Vector Vaccines, Vaccine Research, Vaccine Manufacturing, Disease Prevention, Immunology, Biotechnology, Global Health, Vaccine Distribution, Pharmaceutical Technology |
| Competitors | EpiVax, Inc., Biomax Informatics AG, Ortho Clinical Diagnostics, Synavax™, ProVax, COREVAX (view competitors) |
Looking for a particular CastleVax employee's phone or email?
Michael Egan is the CEO and CSO of CastleVax.
4 people are employed at CastleVax.